Source: The Insides® Company Limited
On: 31st March, 2023
Companies: The Insides® Company Limited
The Insides Company is proud to announce the launch of The Insides® Neo, a world-first chyme reinfusion solution for pediatric and neonatal patients with severe intestinal failure.
Intestinal failure in neonatal and pediatric patients is most commonly caused by necrotising enterocolitis, a severe condition with mortality rates as high as 50%, making it one of the leading causes of death in preterm infants.
Current management includes the formation of double enterostomy and patients will often present with high-output stoma losses resulting in dehydration and malnutrition.
The Insides Neo is a purpose-built chyme reinfusion solution for reinfusing the intestinal losses in pediatric and neonatal patients with double enterostomies suffering from intestinal failure.
The Insides Neo offers significant benefits compared to the current standard of care by meeting the patient’s nutritional and fluid requirements, reducing surgical and ostomy complications and improving clinical workflow for healthcare professionals by reducing manual labor.
The Insides Neo’s New Zealand launch will take place at the National Intestinal Failure & Rehabilitation Services (NZ NIFRS) Annual Education and Training Day on the 31st March.
Rob Davidson, Chief Technology Officer at The Insides Company said “With the release of this product, we are well on our path to achieving our mission to provide universal access to chyme reinfusion therapy. These newborns have now been given an alternative method of treatment, which will deliver essential nutrients that a baby with intestinal failure needs to thrive.”
About The Insides Company
The Insides Company Limited is a leading provider of automated chyme reinfusion solutions for the therapeutic treatment of intestinal failure that has resulted from either a high-output enterocutaneous fistula or enterostomy.
The Insides® Company
Garth Sutherland, CEO
Phone: +64 9 887 9309